The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179369 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Beate Gündel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Cancer Research Lab, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, SE 141 86 Huddinge, Swede…. Hauptthemen laut MEDLINE: Deoxycytidine, Cysteine-Rich Protein 61, Gemcitabine, Pancreatic Stellate Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the EU, Vetenskapsrådet, RaHFo.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that is almost entirely resistant to conventional chemotherapy and radiation therapy. A significant factor in this resistance appears to be the dense desmoplastic stroma, which contains various cancer-associated fibroblast (CAF) populations. However, our understanding of the communication between tumor cells and CAFs that contributes to this aggressive malignancy is still developing. Recently, we used an advanced three-dimensional heterospecies, heterospheroid co-culture model to investigate the signaling between human pancreatic tumor Panc1 cells and mouse pancreatic stellate cells (mPSCs) through global expression profiling. Upon discovering that CCN1 was significantly upregulated in Panc1 cells during co-culture, we decided to explore the role of CCN1 using CRISPR-Cas9 knockout technology. Panc1 cells lacking CCN1 showed reduced differentiation and decreased sensitivity to gemcitabine, primarily due to lower expression of genes involved in gemcitabine transport and metabolism. Additionally, we observed that stimulation with TGF-β1 and lysophosphatidic acid increased CCN1 expression in Panc1 cells and induced a shift in mPSCs towards a more myofibroblastic CAF-like phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pancreas Cancer Research Lab, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, SE 141 86 Huddinge, Sweden.
- Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany.
ORCID-Profile: Veronika Engelsberger, Ralf Weiskirchen, J-Matthias Löhr, Rainer Heuchel
Förderung
- the EU
- Vetenskapsrådet
- RaHFo
- CancerFonden
- China ScholarshipCouncil
Zitieren
APA
Gündel, B., Liu, X., Pfützenreuter, A., Engelsberger, V., Weiskirchen, R., Löhr, J. M., & Heuchel, R. (2024). The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179369
Vancouver
Gündel B, Liu X, Pfützenreuter A, Engelsberger V, Weiskirchen R, Löhr JM, et al. The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179369
BibTeX
@article{Gndel2024,
author = {Gündel, Beate and Liu, Xinyuan and Pfützenreuter, Anna and Engelsberger, Veronika and Weiskirchen, Ralf and Löhr, J-Matthias and Heuchel, Rainer},
title = {The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179369}
}
EUVIMED